Genetic makeup is recognized increasingly as a tool to identify appropriate antidepressant medication. Other examples include genetic testing for cytomegalovirus infection and ganciclovir resistance in transplants as well as testing for primary versus secondary membranous nephrology. This session explores current uses - and the future potential - of genetic testing for disease management.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 5/25/2024.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online nursing continuing professional development (NCPD) evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.
Disclosure of relevant financial relationships with ineligible companies (planners, faculty/speakers, reviewers):
Planning Committee Disclosures: There are no Planning Committee disclosures to declare.
Speaker Disclosures: Mary Schira, PhD, APRN, ACNP-BC is a Speaker for the Baxter Peer Program and invited participant of VoxMedia Hyperkalemia Program at 2022 Symposium.
There are no other speaker disclosures to declare.
Commercial Support: No commercial support declared.
Accreditation Statement: The American Nephrology Nurses Association (ANNA) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
ANNA is an approved provider of continuing nursing education by the California Board of Registered Nursing, Provider Number CEP 17499.
ANNA urges participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.
Learning Outcome: Upon completion of this activity, the learner will be able to discuss the use of genetic testing for diseases that a patient with CKD may also experience.
PhD, RN, ACNP-BC,
Clinical Associate Professor,
University of Texas at Arlington